CRVS Covered Call Strategy
CRVS (Corvus Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis.
CRVS (Corvus Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.27B, a beta of 0.87 versus the broader market, a 52-week range of 4.7-26.95, average daily share volume of 1.4M, a public-listing history dating back to 2016, approximately 37 full-time employees. These structural characteristics shape how CRVS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.87 places CRVS roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a covered call on CRVS?
A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.
CRVS snapshot
As of August 14, 2026, spot at $14.75, ATM IV 63.70%, IV rank 19.50%, expected move 18.26%. The covered call on CRVS below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 63-day expiry.
Why this covered call structure on CRVS specifically: CRVS IV at 63.70% is on the cheap side of its 1-year range, which means a premium-selling CRVS covered call collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 18.26% (roughly $2.69 on the underlying). The 63-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CRVS expiries trade a higher absolute premium for lower per-day decay. Position sizing on CRVS should anchor to the underlying notional of $14.75 per share and to the trader's directional view on CRVS stock.
CRVS covered call setup
The CRVS covered call below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CRVS at $14.75 on that close, the first option leg uses a $15.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CRVS chain at a 63-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CRVS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $14.75 | long |
| Sell 1 | Call | $15.00 | $1.58 |
CRVS covered call risk and reward
- Net Premium / Debit
- -$1,317.50
- Max Profit (per contract)
- $182.50
- Max Loss (per contract)
- -$1,316.50
- Breakeven(s)
- $13.18
- Risk / Reward Ratio
- 0.139
Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.
CRVS covered call payoff curve
Modeled P&L at expiration across a range of underlying prices for the covered call on CRVS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -99.9% | -$1,316.50 |
| $3.27 | -77.8% | -$990.48 |
| $6.53 | -55.7% | -$664.46 |
| $9.79 | -33.6% | -$338.44 |
| $13.05 | -11.5% | -$12.42 |
| $16.31 | +10.6% | +$182.50 |
| $19.57 | +32.7% | +$182.50 |
| $22.83 | +54.8% | +$182.50 |
| $26.09 | +76.9% | +$182.50 |
| $29.35 | +99.0% | +$182.50 |
When traders use covered call on CRVS
Covered calls on CRVS are an income strategy run on existing CRVS stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
CRVS thesis for this covered call
The market-implied 1-standard-deviation range for CRVS extends from approximately $12.06 on the downside to $17.44 on the upside. A CRVS covered call collects premium on an existing long CRVS position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether CRVS will breach that level within the expiration window. Current CRVS IV rank near 19.50% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CRVS at 63.70%. As a Healthcare name, CRVS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CRVS-specific events.
CRVS covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CRVS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CRVS alongside the broader basket even when CRVS-specific fundamentals are unchanged. Short-premium structures like a covered call on CRVS carry tail risk when realized volatility exceeds the implied move; review historical CRVS earnings reactions and macro stress periods before sizing. Always rebuild the position from current CRVS chain quotes before placing a trade.
Frequently asked questions
- What is a covered call on CRVS?
- A covered call on CRVS is the covered call strategy applied to CRVS (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With CRVS stock at $14.75 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed CRVS chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are CRVS covered call max profit and max loss calculated?
- Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the CRVS covered call priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 63.70%), the computed maximum profit is $182.50 per contract and the computed maximum loss is -$1,316.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CRVS covered call?
- The breakeven for the CRVS covered call priced on this page is roughly $13.18 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The CRVS market-implied 1-standard-deviation expected move in the same options snapshot is approximately 18.26%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a covered call on CRVS?
- Covered calls on CRVS are an income strategy run on existing CRVS stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
- How does current CRVS implied volatility affect this covered call?
- CRVS ATM IV is at 63.70% with IV rank near 19.50%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.